Death domain containing receptors

• US 6,759,513 B2
• Filed: 06/16/1999
• Issued: 07/06/2004
• Est. Priority Date: 03/12/1996
• Status: Expired due to Term

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Yu, Guo-Liang, Gentz, Reiner L., Ni, Jian, Dillon, Patrick J.
• Primary Examiner(s): Ulm, John D.
• Application Number:
  US09/333,966
• Publication Number:
  US 20020009773A1
• Time in Patent Office: 1,847 Days
• Field of Search: 530/350, 514/2
• US Class Current: 530/350
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151

Abstract

The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

Claims

1. An isolated protein comprising amino acids 30 to 215 of SEQ ID NO:

2.

2. The isolated protein of claim 1, which comprises amino acids 1 to 215 of SEQ ID NO:

2.

3. The isolated protein of claim 1, which is produced by a recombinant host cell.

4. The isolated protein of claim 1, which comprises a heterologous polypeptide.

5. A composition comprising the isolated protein of claim 1 and a pharmaceutically acceptable carrier.

12. The isolated protein of claim 1, which comprises 50 contiguous amino acids of a polypeptide having the amino acid sequence from 350 to 420 of SEQ ID NO:

2.

13. The isolated protein of claim 12, which comprises amino acids 350 to 420 of SEQ ID NO:

2.

6. An isolated protein comprising the mature amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97456.

7. The isolated protein of claim 6, which comprises the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97456.

8. The isolated protein of claim 6, which is produced by a recombinant host cell.

9. The isolated protein of claim 6, which comprises a heterologous polypeptide.

10. A composition comprising the isolated protein of claim 6 and a pharmaceutically acceptable carrier.

11. An isolated protein comprising 4, contiguous amino acids of a polypeptide having the amino acid sequence from 350 to 420 of SEQ ID NO:

2.

14. The isolated protein of claim 11, which is produced by a recombinant host cell.

15. The isolated protein of claim 11, which comprises a heterologous polypeptide.

16. A composition comprising the isolated protein of claim 11, and a pharmaceutically acceptable carrier.